Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Watching Muscle Maker; Traders Circulate PennyStocks.com Article ‘Best Penny Stocks To Buy Now? 5 To Watch Before Next Week’ Mentioning Stock
https://pennystocks.com/featured/2021/11/04/best-penny-stocks-to-buy-now-5-to-watch-next-week/
Owlet Says Is Developing New Sleep Monitoring Sock, Plans To Submit Application To FDA Seeking Authorization For Features Of Smart Sock
The Company also announced that it is developing a new sleep monitoring sock that it plans to sell as a consumer wellness product, which the Company believes does not present the same concerns that FDA has raised
Owlet Says Pursuant To Warning Letter And In Response To Request By FDA, Co. Has Suspended Distribution Of Smart Sock In US As Of October 22, 2021
On October 25, 2021, Owlet, Inc. (the "Company") provided an update to certain investors regarding recent developments with its Smart Sock suspension and related Company actions. The communication is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Citigroup Maintains Neutral on Owlet, Lowers Price Target to $5
Citigroup maintains Owlet (NYSE:OWLT) with a Neutral and lowers the price target from $12 to $5.
B of A Securities Downgrades Owlet to Neutral, Lowers Price Target to $5.5
B of A Securities analyst John Babcock downgrades Owlet (NYSE:OWLT) from Buy to Neutral and lowers the price target from $8.5 to $5.5.
44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
Owlet Shares Fall On FDA Warning Letter For Smart Sock
Owlet Inc (NYSE:OWLT) stock has dropped almost 24% in the trading session due to receiving a Warning Letter dated October 1,…
30 Stocks Moving In Monday’s Mid-Day Session
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.